Scotiabank analyst George Farmer lowered the firm’s price target on Sage Therapeutics (SAGE) to $14 from $17 and keeps an Outperform rating on the shares. With only a few quarters of sales, the launch of zurzuvae appears to be on-track, the analyst tells investors. The firm assumes a dalzanemdor miss in the DIMENSION Huntington’s disease study expected to read out this year, which will likely lead to further cuts.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
- Sage Therapeutics price target lowered to $14 from $25 at H.C. Wainwright
- Sage Therapeutics Reports Q3 Growth and Strategic Focus
- Sage Therapeutics reports Q3 EPS ($1.53) , consensus ($1.53)
- SAGE Therapeutics, Inc. (US) (SAGE) Q3 Earnings Cheat Sheet